Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Pembrolizumab and indoximod for melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.04.17
Views: 1344

Prof Yousef Nabih Zakharia - Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA

Prof Zakharia speaks with ecancer at AACR 2017 about adding indoximod, an IDO inhibitor, to pembrolizumab to treat advanced melanoma.

In this interim report of results from 102 patients, he highlights that 52% of all patients respond, and that those figures increase when discounting patients with aggressive ocular melanoma.

Compared to phase III single agent studies of pembrolizumab, these results are a marked improvement in response with minimal added toxicity, though Dr Zakharia cautions against direct comparison before further trials conclude.

You can read more about these findings here.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence